Produced:Article Title: Safety of 6′‐sialyllactose (6′‐ SL ) sodium salt produced with a derivative strain ( Escherichia coli K‐12 MG1655 INB ‐6SL_02) of E. coli K‐12 MG1655 ( ATCC 700926) as a novel food pursuant to Regulation ( EU ) 2015/2283
Article Snippet: .. The sodium salts of 6′‐sialyllactose (6′‐SL) and 3′‐sialyllactose (3′‐SL), a constitutional isomer of 6′‐SL, are included in the Union list of authorised NFs (Commission Implementing Regulation (EU) 2017/2470 ) when produced by fermentation with genetically modified strains of Escherichia coli K‐12 DH1, E. coli BL21 (DE3) or E. coli W (ATCC 9637) (EFSA NDA Panel, , , , , , ). .. Since 2015, several scientific opinions with positive outcomes have been adopted by the EFSA NDA Panel on the safety of human‐identical milk oligosaccharides (HiMOs) as NFs pursuant to Regulation (EC) No 258/97 or Regulation (EU) 2015/2283: Chemically synthetised 2′‐fucosyllactose (2′‐FL) (EFSA NDA Panel, ) and 2′‐FL produced with genetically modified strains of Corynebacterium glutamicum ATCC 13032 (EFSA NDA Panel, ) or E. coli W (ATCC 9637) (EFSA NDA Panel, ); Chemically synthesised lacto‐N‐neotetraose (LNnT) (EFSA NDA Panel, ) and LNnT produced with genetically modified strains of E. coli BL21 (DE3) (EFSA NDA Panel, ); Extension of use in food supplements (FS) for children of chemically synthetised 2′‐FL and LNnT (EFSA NDA Panel, ); extension of use in FS for infants of 2′‐FL and LNnT produced with genetically modified strains of E. coli K‐12 DH1 (EFSA NDA Panel, ); and extension of use in infant formula (IF) and follow‐on formula (FOF) of 2′‐FL produced with a genetically modified strain of E. coli BL21 (DE3) (EFSA NDA Panel, ); Chemically synthetised N‐acetyl‐d‐neuraminic acid (NANA) (EFSA NDA Panel, ); 2′‐FL/difucosyllactose (DFL) mixture produced with a genetically modified strain of E. coli K‐12 DH1 (EFSA NDA Panel, ); Lacto‐N‐tetraose (LNT) produced with genetically modified strains of E. coli K‐12 DH1 (EFSA NDA Panel, ), E. coli BL21 (DE3) (EFSA NDA Panel, ) or E. coli K‐12 MG1655 (EFSA NDA Panel, ); Extension of use in FS for infants of 2′‐FL/DFL mixture and LNT produced with genetically modified strains of E. coli K‐12 DH1 (EFSA NDA Panel, ); 3‐fucosyllactose (3‐FL) produced with genetically modified strains of E. coli K‐12 MG1655 (EFSA NDA Panel, ), E. coli BL21 (DE3) (EFSA NDA Panel, ) or E. coli K‐12 DH1 (EFSA NDA Panel, ); and extension of use in IF, FOF, FS and food for special medical purposes (FSMP) of 3‐FL produced with a genetically modified strain of E. coli BL21 (DE3) (EFSA NDA Panel, ); 6′‐sialyllactose (6′‐SL) sodium salts produced with genetically modified strains of E. coli K‐12 DH1 (EFSA NDA Panel, ), E. coli BL21 (DE3) (EFSA NDA Panel, ) or E. coli W (ATCC 9637) (EFSA NDA Panel, ); 3′‐sialyllactose (3′‐SL) sodium salts produced with genetically modified strains of E. coli K‐12 DH1 (EFSA NDA Panel, ), E. coli BL21 (DE3) (EFSA NDA Panel, ) or E. coli W (ATCC 9637) (EFSA NDA Panel, ); Lacto‐N‐fucopentaose I/2′‐FL (LNFP‐I/2′‐FL) mixture produced with a genetically modified strain of E. coli K‐12 DH1 (EFSA NDA Panel, ); Scientific and technical assistance report on the evaluation of HiMOs as NFs (EFSA, ).
Genetically Modified:Article Title: Safety of 6′‐sialyllactose (6′‐ SL ) sodium salt produced with a derivative strain ( Escherichia coli K‐12 MG1655 INB ‐6SL_02) of E. coli K‐12 MG1655 ( ATCC 700926) as a novel food pursuant to Regulation ( EU ) 2015/2283
Article Snippet: .. The sodium salts of 6′‐sialyllactose (6′‐SL) and 3′‐sialyllactose (3′‐SL), a constitutional isomer of 6′‐SL, are included in the Union list of authorised NFs (Commission Implementing Regulation (EU) 2017/2470 ) when produced by fermentation with genetically modified strains of Escherichia coli K‐12 DH1, E. coli BL21 (DE3) or E. coli W (ATCC 9637) (EFSA NDA Panel, , , , , , ). .. Since 2015, several scientific opinions with positive outcomes have been adopted by the EFSA NDA Panel on the safety of human‐identical milk oligosaccharides (HiMOs) as NFs pursuant to Regulation (EC) No 258/97 or Regulation (EU) 2015/2283: Chemically synthetised 2′‐fucosyllactose (2′‐FL) (EFSA NDA Panel, ) and 2′‐FL produced with genetically modified strains of Corynebacterium glutamicum ATCC 13032 (EFSA NDA Panel, ) or E. coli W (ATCC 9637) (EFSA NDA Panel, ); Chemically synthesised lacto‐N‐neotetraose (LNnT) (EFSA NDA Panel, ) and LNnT produced with genetically modified strains of E. coli BL21 (DE3) (EFSA NDA Panel, ); Extension of use in food supplements (FS) for children of chemically synthetised 2′‐FL and LNnT (EFSA NDA Panel, ); extension of use in FS for infants of 2′‐FL and LNnT produced with genetically modified strains of E. coli K‐12 DH1 (EFSA NDA Panel, ); and extension of use in infant formula (IF) and follow‐on formula (FOF) of 2′‐FL produced with a genetically modified strain of E. coli BL21 (DE3) (EFSA NDA Panel, ); Chemically synthetised N‐acetyl‐d‐neuraminic acid (NANA) (EFSA NDA Panel, ); 2′‐FL/difucosyllactose (DFL) mixture produced with a genetically modified strain of E. coli K‐12 DH1 (EFSA NDA Panel, ); Lacto‐N‐tetraose (LNT) produced with genetically modified strains of E. coli K‐12 DH1 (EFSA NDA Panel, ), E. coli BL21 (DE3) (EFSA NDA Panel, ) or E. coli K‐12 MG1655 (EFSA NDA Panel, ); Extension of use in FS for infants of 2′‐FL/DFL mixture and LNT produced with genetically modified strains of E. coli K‐12 DH1 (EFSA NDA Panel, ); 3‐fucosyllactose (3‐FL) produced with genetically modified strains of E. coli K‐12 MG1655 (EFSA NDA Panel, ), E. coli BL21 (DE3) (EFSA NDA Panel, ) or E. coli K‐12 DH1 (EFSA NDA Panel, ); and extension of use in IF, FOF, FS and food for special medical purposes (FSMP) of 3‐FL produced with a genetically modified strain of E. coli BL21 (DE3) (EFSA NDA Panel, ); 6′‐sialyllactose (6′‐SL) sodium salts produced with genetically modified strains of E. coli K‐12 DH1 (EFSA NDA Panel, ), E. coli BL21 (DE3) (EFSA NDA Panel, ) or E. coli W (ATCC 9637) (EFSA NDA Panel, ); 3′‐sialyllactose (3′‐SL) sodium salts produced with genetically modified strains of E. coli K‐12 DH1 (EFSA NDA Panel, ), E. coli BL21 (DE3) (EFSA NDA Panel, ) or E. coli W (ATCC 9637) (EFSA NDA Panel, ); Lacto‐N‐fucopentaose I/2′‐FL (LNFP‐I/2′‐FL) mixture produced with a genetically modified strain of E. coli K‐12 DH1 (EFSA NDA Panel, ); Scientific and technical assistance report on the evaluation of HiMOs as NFs (EFSA, ).
|
ATCC is a verified supplier 
ATCC manufactures this product 